Alexion Pharmaceuticals (ALXN -3.3%) dips after Citigroup intitiates coverage with a tepid Neutral rating, saying its current risk/reward profile isn't attractive. The firm notes that ALXN is presently trading at a very high P/E multiple that reflects optimistic expectations for upward EPS revisions. If history is a guide, the company will need to post significant upside surprises to offset the natural multiple contraction that is likely ahead. [View news story]
WOW----leading edge research ! I wonder if this "analyst" will be one of the 11,000 employees on the chopping block ?
Alexion Pharmaceuticals: On The Road From Orphan Drugs To Blockbuster Profits [View article]
When you compare ALXN with other biotechnology companies it stands out as unique with no peers in the world. Factor in the outstanding management which has been led by a great CEO who founded the company over 20 years ago and you have a great recipe for successful investing.
No reason to think that the author remotely understands the technology or why it remotely stands a chance to be a technological game changer. When you're quickly off to comment on the retail industry before doubling back to update the world on the offshore energy industry, with a pit-stop in micro biotech -- then it becomes quite apparent that "rifle-shooting" from biotech to energy back to retail off to disrutive new technology renders the "author"....... ajack of all trades ? master of none ???
When you churn out as many articles as you can it sure is easy to miss many relevant facts. When you get paid by piece it's virtually impossible to do any significant due diligence or develop any notable experience in so many fields. When you never know who is running a company nor met any of them and strictly relying on second-hand observations from others of course you're not going to have a detailed picture of what a company really does. It's just another opinion and shouldn't be valued any more than that.
Dynavax Shares Jump On Release Of FDA Briefing Materials [View article]
As if the FDA didn't know who was on the advisory committee ! They have to submit all pertinent data......or wasn't that known to you ?? The last time I checked there were more than one vote against.
MLV & Co Sees 146% Upside For Dynavax Technologies' Shares [View article]
"Paid bashers" ???? You must mean the people PAID to write articles for Seeking Alpha----who write to get paid. They're not analysts, qualified portfolio managers or seasoned investors but people who throw some stuff together & taken as gospel by people who rely on them for investment advice.
MLV & Co Sees 146% Upside For Dynavax Technologies' Shares [View article]
"I didn't miss anything"......you sure about that ??? Didn't miss ANYTHING ??? Maybe you shouldn't take the information that gets handed out as gospel next time.
Hess Is On A Roll After Crushing Estimates [View article]
How are you doing on your great DVAX recommendation.....or did you forget that one ????? I bet you're writing up some other "great" company at the moment so you can get paid. Good to see you winging it on a daily basis. It's too bad you bring down Jimmy "what's the chart look like??" Cramer on this one with you.
Dynavax Shares Jump On Release Of FDA Briefing Materials [View article]
Well they have about 75c in cash & some optionality but other than that the BofD should be taken out & shot from their uns=disclosed actions this year.
Dynavax Shares Jump On Release Of FDA Briefing Materials [View article]
Great call on DVAX ! You really had this one "well researched" ! I guess Dino may get to finally go away even though the board can't find anyone to take his CEO job.
Ariad: A Very Interesting Biotech With An Even More Promising Pipeline [View article]
Maybe do a little more homework when you're writing all of these SA articles. You can even call the companies---they can help give you some information that you don't regurgitate from some analyst report.
Alexion Pharmaceuticals (ALXN -3.3%) dips after Citigroup intitiates coverage with a tepid Neutral rating, saying its current risk/reward profile isn't attractive. The firm notes that ALXN is presently trading at a very high P/E multiple that reflects optimistic expectations for upward EPS revisions. If history is a guide, the company will need to post significant upside surprises to offset the natural multiple contraction that is likely ahead. [View news story]
Alexion Pharmaceuticals: On The Road From Orphan Drugs To Blockbuster Profits [View article]
Betting Splunk Goes Splat [View article]
Betting Splunk Goes Splat [View article]
Betting Splunk Goes Splat [View article]
Dynavax Shares Jump On Release Of FDA Briefing Materials [View article]
4 Rallying Hedge Fund Picks Trading Under $5 [View article]
MLV & Co Sees 146% Upside For Dynavax Technologies' Shares [View article]
MLV & Co Sees 146% Upside For Dynavax Technologies' Shares [View article]
MLV & Co Sees 146% Upside For Dynavax Technologies' Shares [View article]
4 Rallying Hedge Fund Picks Trading Under $5 [View article]
Hess Is On A Roll After Crushing Estimates [View article]
Dynavax Shares Jump On Release Of FDA Briefing Materials [View article]
Dynavax Shares Jump On Release Of FDA Briefing Materials [View article]
Ariad: A Very Interesting Biotech With An Even More Promising Pipeline [View article]